Arsenic-transformed malignant prostate epithelia can convert noncontiguous normal stem cells into an oncogenic phenotype

Environmental Health Perspectives

Volumn 120, Issue 6, 2012, Pages 865-871

  Xu, Yuanyuan ^a   Tokar, Erik J ^a   Sun, Yang ^a   Waalkes, Michael P ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Arsenic; Cancer stem cells; Interluekin 6; Prostate; Stem cells

Indexed keywords

ARSENIC; BMI1 PROTEIN; GELATINASE A; GELATINASE B; INTERLEUKIN 6; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P63; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; WNT3 PROTEIN;

ARTICLE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL INVASION; CELL RENEWAL; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MALIGNANT TRANSFORMATION; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE EPITHELIUM; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SPHEROID; WESTERN BLOTTING;

ARSENIC; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; MALE; MATRIX METALLOPROTEINASES; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84862001935     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1204987     Document Type: Article

References (46)

1. Achanzar WE, Brambila EM, Diwan BA, Webber MM, Waalkes MP. 2002. Inorganic arsenite-induced malignant transformation of human prostate epithelial cells. J Natl Cancer Inst 94:1888-1891.
2. Azevedo A, Cunha V, Teixeira AL, Medeiros R. 2011. IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol 2:384-396.
3. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS. 1997. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 18:1215-1223.
4. Bomken S, Fiser K, Heidenreich O, Vormoor J. 2010. Understanding the cancer stem cell. Br J Cancer 103:439-445.
5. Bonnet D, Dick JE. 1997. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730-737.
6. Borovski T, De Sousa EMF, Vermeulen L, Medema JP. 2011. Cancer stem cell niche: the place to be. Cancer Res 71:634-639.
7. Das S, Santra A, Lahiri S, Guha Mazumder DN. 2005. Implications of oxidative stress and hepatic cytokine (TNF-a and IL-6) response in the pathogenesis of hepatic collagenesis in chronic arsenic toxicity. Toxicol Appl Pharmacol 204:18-26.
8. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C, et al. 2009. The role of PTEN/AKT/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA 106:268-273.
9. Hochedlinger K, Yamada Y, Beard C, Jaenisch R. 2005. Ectopic expression of OCT-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 121:465-477.
10. IARC (International Agency for Research on Cancer). 1973. Arsenic and inorganic compounds. IARC Monogr Eval Carcinog Risk Hum 2:48-73.
11. IARC (International Agency for Research on Cancer). 2011. Arsenic and arsenic compounds. IARC Monogr Eval Carcinog Risk Hum 100C:41-94.
12. Iliopoulos D, Hirsch HA, Wang G, Struhl K. 2010. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci USA 108:1397-1402.
13. Kang Y, Massague J. 2004. Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell 118:277-279.
14. Kojima C, Ramirez DC, Tokar EJ, Himeno S, Drobna Z, Styblo M, et al. 2009. Requirement of arsenic biomethylation for oxidative DNA damage. J Natl Cancer Inst 101:1670-1681.
15. Korkaya H, Liu S, Wicha MS. 2011. Regulation of cancer stem cells by cytokine networks: Attacking cancer's inflammatory roots. Clin Can Res 17:6125-6129.
16. Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, FaberJ, et al. 2006. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442:818-822.
17. Lee P-C, Ho I-C, Lee T-C. 2005. Oxidative stress mediates sodium arsenite-induced expression of heme oxygenase-1, monocyte chemoattractant protein-1, and interleukin-6 in vascular smooth muscle cells. Toxicol Sci 85:541-550.
18. Leong KG, Gao WQ. 2008. The notch pathway in prostate development and cancer. Differentiation 76:699-716.
19. Lessard J, Sauvageau G. 2003. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423:255-260.
20. Liao CP, Adisetiyo H, Liang M, Roy-Burman P. 2010. Cancer-associated fibroblasts enhance the gland-forming capability of prostate cancer stem cells. Cancer Res 70:7294-7303.
21. Litvinov IV, Vander Griend DJ, Xu Y, Antony L, Dalrymple SL, Isaacs JT. 2006. Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. Cancer Res 66:8598-8607.
22. Lukacs RU, Memarzadeh S, Wu H, Witte ON. 2010. Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell 7:682-693.
23. Nylander K, Vojtesek B, Nenutil R, Lindgren B, Roos G, Zhanxiang W, et al. 2002. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol 198:417-427.
24. Pardal R, Clarke MF, Morrison SJ. 2003. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3:895-902.
25. Patterson TJ, Reznikova TV, Phillips MA, Rice RH. 2005. Arsenite maintains germinative state in cultured human epidermal cells. Toxicol Appl Pharmacol 207:69-77.
26. Rojas A, Liu G, Coleman I, Nelson PS, Zhang M, Dash R, et al. 2011. IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IFG-IR. Oncogene 30:2345-2355.
27. Rosen JM, Jordan CT. 2009. The increasing complexity of the cancer stem cell paradigm. Science 324:1670-1673.
28. Schalken JA, van Leenders G. 2003. Cellular and molecular biology of the prostate: Stem cell biology. Urology 62:11-20.
29. Senoo M, Pinto F, Crum CP, McKeon F. 2007. p63 is essential for the proliferative potential of stem cells in stratified epithelia. Cell 129:523-536.
30. Somervaille TC, Cleary ML. 2006. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 10:257-268.
31. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, et al. 2006. Purification and unique properties of mammary epithelial stem cells. Nature 439:993-997.
32. Sun Y, Tokar EJ, Waalkes MP. 2012. Overabundance of putative cancer stem cells in human skin keratinocyte cells malignantly transformed by arsenic. Toxicol Sci 125:20-29.
33. Suzuki K, Sun R, Origuchi M, Kanehira M, Takahata T, Itoh J, et al. 2011. Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization. Mol Med 17:579-587.
34. Tokar EJ, Ancrile BB, Cunha GR, Webber MM. 2005. Stem/progenitor and intermediate cell types and the origin of human prostate cancer. Differentiation 73:463-473.
35. Tokar EJ, Diwan BA, Waalkes MP. 2010a. Arsenic exposure transforms human epithelial stem/progenitor cells into a cancer stem-like phenotype. Environ Health Perspect 118:108-115.
36. Tokar EJ, Diwan BA, Ward JM, Delker DA, Waalkes MP. 2011a. Carcinogenic effects of "whole-life" exposure to inorganic arsenic in CD1 mice. Toxicol Sci 119:73-83.
37. Tokar EJ, Qu W, Liu J, Liu W, Webber MM, Phang JM, et al. 2010b. Arsenic-specific stem cell selection during malignant transformation. J Natl Cancer Inst 102:638-649.
38. Tokar EJ, Qu W, Waalkes MP. 2011b. Arsenic, stem cells, and the developmental basis of adult cancer. Toxicol Sci 120 Suppl 1:S192-S203.
39. Verhagen PC, van Duijn PW, Hermans KG, Looijenga LH, van GurpRJ, Stoop H, et al. 2006. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J Pathol 208:699-707.
40. Vermeulen L, De Sousa EMF, van der Heijden M, Cameron K, de Jong JH, Borovski T, et al. 2010. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 12:468-476.
41. Visvader JE, Lindeman GJ. 2008. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 8:755-768.
42. Waalkes MP, Liu J, Diwan BA. 2007. Transplacental arsenic carcinogenesis in mice. Toxicol Appl Pharmacol 222:271-280.
43. Waalkes MP, Liu J, Germolec DR, Trempus CS, Cannon RE, Tokar EJ, et al. 2008. Arsenic exposure in utero exacerbates skin cancer response in adulthood with contemporaneous distortion of tumor stem cell dynamics. Cancer Res 68:8278-8285.
44. Wang JC. 2010. Good cells gone bad: the cellular origins of cancer. Trends Mol Med 16:145-151.
45. Wang S, Garcia AJ, Wu M, Lawson DA, Witte ON, Wu H. 2006. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci USA 103:1480-1485.
46. Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, Chang HY. 2008. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2:333-344.